Latest News-WuXi Biologics Mediaroom_Page

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-03-02 11:21 6690

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Researc...

2026-02-03 11:22 9714

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-29 10:39 9424

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Researc...

2026-01-26 17:35 16345

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 comme...

2026-01-15 12:00 8203

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 9484

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 12259

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-12 21:09 9435

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20...

2026-01-05 11:57 8012

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named t...

2025-12-19 17:30 5548

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

* The only company from pharmaceutical industry selected for inclusion in the Index * Also incl...

2025-10-22 08:30 3547

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...

2025-10-10 08:30 1946

WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability

* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integratio...

2025-09-25 19:42 2459

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules

* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quali...

2025-08-11 16:30 2950

Latest News

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability

WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry

WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi

WuXi Biologics Reports Solid 2025 Interim Results

WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules